Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Guang-Shing ChengVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0003-4324-9634
Angela P CampbellVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0003-3990-3656
Hu XieVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0003-0556-6591
Chikara OgimiVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0002-2166-8152
Alpana WaghmareVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0003-2268-9470
Jane KuypersDepartment of Laboratory Medicine & Pathology, University of Washington, Seattle, Washington, USA.
W Garrett NicholsVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Paul CarpenterDepartment of Pediatrics,University of Washington, Seattle, Washington, USA.ORCID 0000-0002-5021-0714
Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Cheryl CallaisVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Brenda M SandmaierClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0002-9767-9739
Terry Stevens-AyersVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Keith R JeromeVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0002-8212-3789
Jason W ChienVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Wendy M LeisenringClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0001-7405-0906
Janet A EnglundVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0003-1134-4178
Michael BoeckhVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0003-1538-7984
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Geoffrey Roger HILL · 1985 to 2026
$128.4M
INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCE (UL1): BPCAUL1RR025014 · NCRR · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2007 to 2011
$51.5M
Project 3: Stem Cell Allografts for Lymphoid MalignanciesP01CA078902 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SANDMAIER, BRENDA MARIE · 1999 to 2025
$46.1M
Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Cell Transplant RecipientsR01HL161037 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Guang-Shing Cheng · 2022 to 2026
$3.8M
Respiratory Viruses and Airflow Obstruction after HCTR01HL081595 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BOECKH, MICHAEL J · 2005 to 2008
$2.5M
Infections in Hematopoietic Cell Transplant RecipientsK24HL093294 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BOECKH, MICHAEL J · 2009 to 2019
$1.5M
Viral and Host Biomarkers of Human Rhinovirus Disease Severity in TransplantationK23AI114844 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI WAGHMARE, ALPANA AMALKANT · 2015 to 2019
$897k
Parainfluenza Virus Infection in Hematopoietic Cell Transplant RecipientsK23HL091059 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI CAMPBELL, ANGELA JEAN PECK · 2008 to 2012
$682k
Impact of Cumulative Exposure to Respiratory Viruses after Allogeneic Hematopoietic Cell TransplantationK23AI139385 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI OGIMI, CHIKARA · 2019 to 2021
$557k
Clinical and Translational Research ULI RR025014MedImmune PediatricNCI NIH HHS P01 CA018029NCI NIH HHS P01 CA078902NCI NIH HHS P30 CA015704NCRR NIH HHS UL1 RR025014NHLBI NIH HHS K23 HL091059NHLBI NIH HHS K24 HL093294NHLBI NIH HHS R01 HL081595NHLBI NIH HHS R01 HL161037NIAID NIH HHS K23 AI114844NIAID NIH HHS K23 AI139385NIAID NIH HHS L40 AI071572Pediatric Infectious Diseases SocietySeattle Children's CenterUS National Institutes of Health K23AI114844US National Institutes of Health K23AI139385US National Institutes of Health K23HL091059US National Institutes of Health K24HL093294US National Institutes of Health L40AI071572US National Institutes of Health P01CA018029US National Institutes of Health P01CA078902US National Institutes of Health P30CA015704US National Institutes of Health R01HL081595US National Institutes of Health R01HL161037
6 · The paper itself
Abstract
backgroundRespiratory virus infections (RVIs) are common after hematopoietic cell transplantation (HCT), but their effect on pulmonary outcomes, including bronchiolitis obliterans syndrome (BOS), and mortality is poorly defined.
methodsProspective cohort study of 471 allogeneic HCT recipients transplanted in the pre-COVID-19 pandemic era in an academic cancer center. Participants were prospectively followed for 1 year with serial handheld spirometry, symptom questionnaires, and multiplex 11-virus PCR. Pulmonary function testing occurred at recommended intervals. Cox proportional hazard and generalized estimating equation models were used to estimate associations between RVI and weekly spirometry with late airflow obstruction (AFO), BOS, and overall mortality.
resultsThe 1-year cumulative incidence of at least one RVI was 62%; lower respiratory tract disease (LRTD) occurred in 7.6% of patients. Late AFO developed in 15.6% of patients and BOS in 3.9% of patients. Any symptomatic viral upper respiratory tract infections (URTI) were associated with AFO (adjusted HR [aHR] 1.87, 95% CI 1.11-3.16) and BOS (aHR 2.65, 95% CI 1.02-6.91). Individually, PIV-3 URTIs were associated with AFO (aHR 2.83, 95% CI 1.01-7.97) and RSV URTIs were associated with BOS (aHR 6.32, 95% CI 2.04-19.6). Short-term airflow decline was associated with AFO. Any LRTD (aHR 3.49, 95% CI 2.18-5.57), as well as symptomatic influenza URTI (aHR 2.68, 95% CI 1.52-4.72), were associated with mortality.
conclusionsRVI after HCT, particularly those caused by RSV, PIV-3, and influenza, increase the risk of pulmonary impairment and mortality. These infections should be targeted for specific anti-viral approaches and intensified monitoring for late onset pulmonary disease.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Respiratory Virus Infections and Pulmonary Impairment After Allogeneic Hematopoietic Cell Transplantation. · full record | OpenQuestion